Takeda reportedly will build a high containment production facility at its site in Dublin, Ireland to support the manufacturing of its oncology product Ninlaro (ixazomib), according to an article in in-Pharma Technologist.
The Japanese manufacturer said it is investing about $43 million to expand its Grange Castle, Dublin, facility and add 40 new jobs. The site is its worldwide center for API manufacturing.
Read the full story